

10/759,749

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI
NEWS 14 JUL 11 CHEMSAFE reloaded and enhanced

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:42:52 ON 14 JUL 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

10/759,749

FILE 'REGISTRY' ENTERED AT 13:43:01 ON 14 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6
DICTIONARY FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10759749.str



chain nodes :

7 8

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

2-8 6-7 8-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

2-8 6-7 8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

isolated ring systems :

containing 1 :

10/759,749

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:43:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 101 TO ITERATE

100.0% PROCESSED 101 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1418 TO 2622

PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1


=> d scan

L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Pyrimidinemethanol, 4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-
(9CI)

MF C14 H18 N6 O2

10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI)


MF C24 H23 N5 O2 . 2 C2 H F3 O2

CM 1



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2



L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Pyrimidinemethanol, 2-[[5-[bis(methoxymethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)- (9CI)

MF C19 H28 N6 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Pyrrolidineacetamide, N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-


10/759,749

pyridinyl]- (9CI)
MF C27 H28 F4 N8 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Ethanone, 1-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI)
MF C15 H19 N7 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Pyrimidinediamine, N4-[2-(diethylamino)ethyl]-6-methyl-N2-2-pyridinyl- (9CI)
MF C16 H24 N6
CI COM



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]- (9CI)
MF C21 H22 N6 O2
CI COM

10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Pyrimidineethanol, 2-[[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)- β,β -dimethyl- (9CI)
MF C24 H38 N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L2 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Pyrimidinecarbonitrile, 4-[[[(4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI)
MF C25 H22 N6 O . 2 C2 H F3 O2


CM 1



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749



ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful

FULL SEARCH INITIATED 13:43:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2101 TO ITERATE

100.0% PROCESSED 2101 ITERATIONS
SEARCH TIME: 00.00.01

172 ANSWERS

L3 172 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 13:43:51 ON 14 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jul 2006 VOL 145 ISS 4

FILE LAST UPDATED: 13 Jul 2006 (20060713/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 15 L3

=> d l4 1-15 bib hitstr

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:293263 CAPLUS

DN 144:350705

TI Substituted pyridine and pyrimidine compounds as pharmaceutical agents, their preparation, pharmaceutical compositions, and use in therapy

IN Andersen, Denise Lyn; Chang, Catherine H.; Falsey, James R.; Frohn,

Michael J.; Hong, Fang-Tsao; Liao, Hongyu; Liu, Longbin; Lopez, Patricia; Retz, Daniel Martin; Rishton, Gilbert M.; Rzasa, Robert M.; Siegmund, Aaron; Tadesse, Seifu; Tamayo, Nuria; Tegley, Christopher M.

PA USA

SO U.S. Pat. Appl. Publ., 86 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006069110	A1	20060330	US 2005-237513	20050927
	WO 2006037117	A1	20060406	WO 2005-US35134	20050927
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-613762P P 20040927

OS MARPAT 144:350705



IT 881209-99-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyridine and pyrimidine compds. as anti-inflammatory, analgesic, or antidiabetic agents)

RN 881209-99-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(1-cyclohexen-1-yl)-2-pyridinyl]-N4-methyl-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:194015 CAPLUS

DN 144:292768

TI Preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors

IN Stadtmueller, Heinz; Engelhardt, Harald; Steegmaier, Martin; Baum, Anke; Guertler, Ulrich; Schoop, Andreas; Quant, Jens; Solca, Flavio; Hauptmann, Rudolf; Reiser, Ulrich; Zahn, Stephan Karl; Herfurth, Lars

PA Boehringer Ingelheim International G.m.b.H., Germany

10/759,749

SO PCT Int. Appl., 272 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021544	A1	20060302	WO 2005-EP54089	20050818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

	US 2006148800	A1	20060706	US 2005-206703	20050817
--	---------------	----	----------	----------------	----------

PRAI	EP 2004-19775	A	20040820		
------	---------------	---	----------	--	--

OS MARPAT 144:292768


IT 878150-13-1P 878150-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)

RN 878150-13-1 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878150-14-2 CAPLUS

CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 878155-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)

RN 878155-93-2 CAPLUS

CN Acetamide, 2-bromo-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-indol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:961232 CAPLUS

DN 143:253451

TI Hair coloring compositions containing phenylenediamine or diaminopyridine couplers and diaminopyrazole intermediates

IN Lim, Mu'llll; Zhang, Guiru; Murphy, Bryan Patrick

PA USA

SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 90,377. CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005188480	A1	20050901	US 2005-77744	20050311
	US 2003196280	A1	20031023	US 2002-90377	20020304


10/759,749

US 6887280 B2 20050503
PRAI US 2002-90377 A2 20020304
OS MARPAT 143:253451
IT 863298-72-0
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair coloring compns. containing phenylenediamine or diaminopyridine
couplers and diaminopyrazole intermediates)
RN 863298-72-0 CAPLUS
CN Pyrimidinetetramine, N2-(6-amino-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:517936 CAPLUS
DN 143:451473
TI Two novel copper(II) complexes with a novel ligand 2,4-Di(2-aminopyridine)-
6-methylpyrimidine
AU Ma, Hai-rui; Wang, Yao-yu; Liu, Ping; Li, Dong-sheng; Shi, Qi-zhen; Lee,
Gene-hsiang; Peng, Shie-ming
CS Department of Chemistry, Northwest University, Xian, 710069, Peop. Rep.
China
SO Chemical Research in Chinese Universities (2005), 21(3), 365-367
CODEN: CRCUED; ISSN: 1005-9040
PB Higher Education Press
DT Journal
LA English
IT 848189-14-0
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(crystal structure and reactant for preparation of copper complexes)
RN 848189-14-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:158646 CAPLUS
 DN 142:254587
 TI Methods for treating or preventing autoimmune diseases with
 2,4-pyrimidinediamine compounds
 IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;
 Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger
 PA Rigel Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 276 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004265288	A1	20050224	AU 2004-265288	20040730
	CA 2533377	AA	20050224	CA 2004-2533377	20040730
	US 2005209224	A1	20050922	US 2004-903870	20040730
	US 2005234049	A1	20051020	US 2004-903263	20040730
	EP 1656372	A2	20060517	EP 2004-786150	20040730
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	WO 2004-US24716	W	20040730		
OS	MARPAT 142:254587				
IT	841290-96-8P 841290-97-9P 841291-02-9P				
	841294-23-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				
	(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				
	(Uses)				
	(pyrimidinediamine compds. for treatment or prevention of autoimmune				
	diseases)				
RN	841290-96-8 CAPLUS				
CN	2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6,6'-[(5-fluoro-2,4-				
	pyrimidinediyl)diimino]bis[2,2,4-trimethyl- (9CI) (CA INDEX NAME)				




10/759,749

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841290-97-9 CAPLUS


CN 4H-Pyrido[3,2-b]-1,4-oxazine-4-acetic acid, 6,6'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[2,3-dihydro-2,2-dimethyl-3-oxo-, dimethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841291-02-9 CAPLUS


CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6,6'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841294-23-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:120923 CAPLUS

DN 142:219300

TI 2,4-Pyrimidinediamines for use in the treatment or prevention of autoimmune diseases

IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar; Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 169 pp.

CODEN: PIXXD2


DT Patent

10/759,749

LA English

FAN.CNT 6


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012294	A1	20050210	WO 2004-US24920	20040730
	WO 2005012294	C1	20051229		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005209224	A1	20050922	US 2004-903870	20040730
	US 2005234049	A1	20051020	US 2004-903263	20040730
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
OS	MARPAT 142:219300				
IT	841290-96-8P 841290-97-9P 841291-02-9P 841294-23-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pyrimidinediamines for use in the treatment or prevention of autoimmune diseases)				
RN	841290-96-8 CAPLUS				
CN	2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6,6'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[2,2,4-trimethyl- (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841290-97-9 CAPLUS


CN 4H-Pyrido[3,2-b]-1,4-oxazine-4-acetic acid, 6,6'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[2,3-dihydro-2,2-dimethyl-3-oxo-, dimethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841291-02-9 CAPLUS


CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6,6'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 841294-23-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:61565 CAPLUS

DN 142:328292

TI Synthesis, characterization and crystal structures of 2,4-di(2-aminopyridine)-6-methylpyrimidine (dapmp), [Cu(dapmp)Cl₂] and [Cu(dapmp)(CH₃COO)₂]·H₂O

AU Ma, Hai-Rui; Wang, Yao-Yu; Liu, Ping; Li, Dong-Sheng; Shi, Qi-Zhen; Lee, Gene-Hsiang; Peng, Shie-Ming

CS Department of Chemistry, Shaanxi Key Laboratory of Physico-Inorganic Chemistry, Northwest University, Xian, 710069, Peop. Rep. China

SO Polyhedron (2005), 24(2), 215-220
CODEN: PLYHDE; ISSN: 0277-5387

PB Elsevier B.V.

DT Journal

LA English


OS CASREACT 142:328292

IT 848189-14-0P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, crystal structure and complexation of bis(pyridinylamino)pyrimidine with copper(II))

RN 848189-14-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:633921 CAPLUS
 DN 141:174079
 TI Preparation of 2-aminopyridines as cdk4 inhibitors
 IN Biwersi, Cathlin Marie; Mcnamara, Dennis Joseph; Repine, Joseph Thomas;
 Toogood, Peter Laurence; Vanderwel, Scott Norman; Warmus, Joseph Scott
 PA Warner-Lambert Company Llc, USA
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Applicants'

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065378	A1	20040805	WO 2004-IB91	20040109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2512646	AA	20040805	CA 2004-2512646	20040109
	EP 1590341	A1	20051102	EP 2004-701058	20040109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006809	A	20051227	BR 2004-6809	20040109
	JP 2006516561	T2	20060706	JP 2006-500296	20040109
	US 2004236084	A1	20041125	US 2004-759749	20040116
PRAI	US 2003-440805P	P	20030117		
	WO 2004-IB91	W	20040109		
OS	MARPAT 141:174079				
IT	733038-85-2P, 4-[6-[[5-Amino-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)				
RN	733038-85-2 CAPLUS				
CN	1-Piperazinecarboxylic acid, 4-[6-[[5-amino-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-77-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester hydrochloride
 733038-80-7P, 4-[6-[[5-Bromo-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester
 733038-83-0P, 4-[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733038-84-1P
 733039-16-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-19-5P,
 5-Bromo-N'-cyclopentyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-29-7P, N'-Cyclopentyl-5-nitro-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-30-0P,
 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-31-1P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester
 733039-32-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-33-3P,
 [4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-34-4P, 1-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-35-5P,
 3-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]but-2-enoic acid ethyl ester 733039-36-6P,
 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-37-7P, 5-Nitro-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-38-8P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-39-9P,
 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester 733039-40-2P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester
 733039-41-3P, [4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-42-4P,
 1-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-43-5P, 3-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]but-2-enoic acid ethyl ester 733039-44-6P
 , 4-Cyclopentylamino-2-[5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-45-7P, N-[5-(3-Aminopyrrolidin-1-yl)pyridin-2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine 733039-46-8P,
 4-Cyclopentylamino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-47-9P, 4-Cyclopentylamino-2-[(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-yl)amino]pyrimidine-5-carboxylic acid ethyl ester 733039-48-0P, 4-Cyclopentylamino-6-methyl-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-49-1P, [2-[5-[Bis(methoxymethyl)amino]pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidin-5-yl]methanol 733039-50-4P
 , 1-[4-Benzylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-51-5P, 4-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]pent-3-en-2-one 733039-52-6P
 , 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carbonitrile 733039-53-7P, 5-Nitro-N-pyridin-2-ylpyrimidine-2,4-diamine 733039-54-8P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carboxaldehyde 733039-55-9P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carboxylic acid ethyl ester 733039-56-0P,

5-Bromo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-57-1P, [4-Amino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-58-2P, 1-[4-Amino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-59-3P, [[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-yl]oxy]acetic acid 733039-60-6P, 4-Cyclopentylamino-2-[4-hydroxymethyl-5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-61-7P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine 733039-62-8P, 2-(5-Bromopyridin-2-ylamino)-4-(cyclopentylamino)pyrimidine-5-carboxaldehyde 733039-63-9P, 4-Cyclopentylamino-2-[(1H-pyrrolo[3,2-b]pyridin-5-yl)amino]pyrimidine-5-carboxylic acid ethyl ester 733039-64-0P, 4-Cyclopentylamino-2-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-ylamino]-6-methylpyrimidine-5-carboxylic acid methyl ester 733039-65-1P, 2-[2-[[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidin-5-yl]-2-methylpropan-1-ol 733039-66-2P, 1-[4-Phenylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-67-3P, 4-[4-(3-Hydroxycyclopentylamino)-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]pyrimidin-5-yl]pent-3-en-2-one 733039-68-4P, 4-[[5-Cyano-2-(pyridin-2-ylamino)pyrimidin-4-yl]amino]cyclohexanecarboxylic acid 733039-69-5P, 2-(4-Amino-5-nitropyrimidin-2-ylamino)isonicotinic acid 733039-70-8P, 4-Amino-6-methyl-2-(pyridin-2-ylamino)pyrimidine-5-carboxaldehyde 733039-71-9P, 5-Iodo-N-pyridin-2-ylpyrimidine-2,4-diamine 733039-72-0P, N-[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]acrylamide 733039-73-1P, N-[5-(Piperazin-1-yl)pyridin-2-yl]-5-prop-1-ynylpyrimidine-2,4-diamine 733039-74-2P, 5-[2-(4-Fluorophenyl)ethyl]-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-75-3P, [[6-(4-Amino-5-allylpyrimidin-2-ylamino)pyridin-3-yl]oxy]acetic acid 733039-76-4P, 5-Bromo-N'-cyclopentyl-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-77-5P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-78-6P, 5-Bromo-N'-cyclopentyl-N-(1H-pyrrolo[3,2-b]pyridin-5-yl)pyrimidine-2,4-diamine 733039-79-7P, 5-Bromo-N'-cyclopentyl-N-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-yl]-6-methylpyrimidine-2,4-diamine 733039-80-0P, N-[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-81-1P, 5-Bromo-N'-phenyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-82-2P, 3-[[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]amino]cyclopentanol 733039-83-3P, N'-Cyclopentyl-5-iodo-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-84-4P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-N'-cyclopentyl-5-iodopyrimidine-2,4-diamine 733039-85-5P, N'-Cyclopentyl-5-iodo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-86-6P, N'-Cyclopentyl-5-iodo-N-(1H-pyrrolo[3,2-b]pyridin-5-yl)pyrimidine-2,4-diamine 733039-87-7P, 4-[6-(4-Cyclopentylamino-5-formylpyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-88-8P, 4-[6-[[5-Acetyl-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-93-5P, 4-[6-[[4-Cyclopentylamino-5-(1-methyl-3-oxobut-1-enyl)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733040-28-3P, 5-Fluoro-N'-isopropyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for

10/759,749

treating cell proliferative disorders)

RN 733038-77-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-80-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[5-bromo-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-83-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-84-1 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-nitro-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-16-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-19-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-29-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-30-0 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




10/759,749

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-31-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-32-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-33-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-34-4 CAPLUS

CN Ethanone, 1-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-35-5 CAPLUS

CN 2-Butenoic acid, 3-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-36-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-37-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-38-8 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-40-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-41-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-42-4 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-43-5 CAPLUS


CN 2-Butenoic acid, 3-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-44-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-pyrrolidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE ~~OR~~ MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-45-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-46-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-47-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperidiny1)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-48-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-6-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-49-1 CAPLUS


CN 5-Pyrimidinemethanol, 2-[[5-[bis(methoxymethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-50-4 CAPLUS

CN Ethanone, 1-[4-[(phenylmethyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-51-5 CAPLUS

CN 3-Penten-2-one, 4-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-52-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-54-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-55-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-(2-pyridinylamino)-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-56-0 CAPLUS

10/759,749


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-57-1 CAPLUS


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-58-2 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-59-3 CAPLUS

CN Acetic acid, [[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]oxy]-
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-60-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[4-(hydroxymethyl)-5-(1-pyrrolidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-61-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-62-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 2-[(5-bromo-2-pyridinyl)amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-63-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-(1H-pyrrolo[3,2-b]pyridin-5-ylamino)-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-64-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]amino]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-65-1 CAPLUS


CN 5-Pyrimidineethanol, 2-[[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)-β,β-dimethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-66-2 CAPLUS


CN Ethanone, 1-[4-(phenylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-67-3 CAPLUS


CN 3-Penten-2-one, 4-[4-[(3-hydroxycyclopentyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-68-4 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[5-cyano-2-(2-pyridinylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-69-5 CAPLUS


CN 4-Pyridinecarboxylic acid, 2-[(4-amino-5-nitro-2-pyrimidinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-70-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-6-methyl-2-(2-pyridinylamino)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-71-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-iodo-N2-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-72-0 CAPLUS

CN 2-Propenamide, N-[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-73-1 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(1-piperazinyl)-2-pyridinyl]-5-(1-propynyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-74-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-[2-(4-fluorophenyl)ethyl]-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-75-3 CAPLUS

CN Acetic acid, [[6-[[4-amino-5-(2-propenyl)-2-pyrimidinyl]amino]-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-76-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-77-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-78-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-(1H-pyrrolo[3,2-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-79-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]-6-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-80-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-bis(2-methoxyethyl)amino]-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)


10/759,749



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-81-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-82-2 CAPLUS


CN Cyclopentanol, 3-[[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-83-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-84-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-iodo- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-85-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-86-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-(1H-pyrrolo[3,2-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-87-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-formyl-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-88-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[5-acetyl-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-93-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-(1-methyl-3-oxo-1-butenyl)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733040-28-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(1-methylethyl)-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 733039-18-4P, 4-[6-[[5-Cyano-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733039-18-4 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[5-cyano-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/759,749

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-79-4, 2-[[5-(4-tert-Butoxycarbonylpiperazin-1-yl)pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidine-5-carboxylic acid ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-aminopyrimidines as cdk4 inhibitors for treating cell proliferative disorders)
RN 733038-79-4 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:236703 CAPLUS
DN 140:423636
TI Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated Aromatic Nucleophilic Substitution
AU Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard S.; Player, Mark R.
CS 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA
SO Journal of Combinatorial Chemistry (2004), 6(3), 414-419
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 140:423636
IT 691402-43-4P 691402-45-6P 691402-61-6P
691402-63-8P 691402-79-6P 691402-81-0P
691402-97-8P 691402-99-0P 691403-15-3P
691403-17-5P 691403-34-6P 691403-36-8P
691403-59-5P 691403-62-0P 691403-86-8P
691403-89-1P 691404-13-4P 691404-16-7P
691404-39-4P 691404-62-3P 691404-65-6P
691404-87-2P 691404-89-4P 691405-08-0P
691405-10-4P 691405-26-2P 691405-28-4P
691405-45-5P 691405-48-8P 691405-64-8P
691405-66-0P 691405-82-0P 691405-84-2P
691406-00-5P 691406-02-7P 691406-08-3P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via Lewis acid-mediated aromatic nucleophilic substitution)
RN 691402-43-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-42-3

10/759,749

CMF C17 H17 N5




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-45-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-44-5

CMF C23 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-61-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

10/759,749

CM 1


CRN 691402-60-5
CMF C15 H19 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691402-63-8 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691402-62-7
CMF C21 H23 N5 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 76-05-1
CMF C2 H F3 O2




10/759,749

RN 691402-79-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
CM 1
CRN 691402-78-5
CMF C18 H19 N5




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 691402-81-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
CM 1
CRN 691402-80-9
CMF C24 H23 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2
CRN 76-05-1
CMF C2 H F3 O2

10/759,749




RN 691402-97-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-96-7

CMF C16 H23 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-99-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-98-9

CMF C22 H27 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749


CRN 76-05-1
CMF C2 H F3 O2



RN 691403-15-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691403-14-2
CMF C18 H17 Cl2 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691403-17-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-16-4

10/759,749

CMF C24 H21 Cl2 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-34-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-33-5

CMF C20 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

10/759,749

CMF C2 H F3 O2




RN 691403-36-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-35-7

CMF C26 H27 N5 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691403-59-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-58-4

CMF C18 H19 N5 O

10/759,749




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-62-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-61-9

CMF C24 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-86-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

10/759,749

CM 1


CRN 691403-85-7
CMF C17 H16 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691403-89-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691403-88-0
CMF C23 H20 F N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




10/759,749

RN 691404-13-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-propyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691404-12-3
CMF C13 H17 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-16-7 CAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-propyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-15-6
CMF C19 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2


10/759,749



RN 691404-39-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691404-38-3
CMF C24 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-62-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-[[tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-61-2
CMF C16 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-65-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-
[[(tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1


CRN 691404-64-5
CMF C22 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691404-87-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[(4-methylphenyl)methyl]amino]-2-[(5-methyl-2-
pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-86-1
CMF C19 H18 N6

10/759,749




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-89-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-88-3

CMF C25 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749




RN 691405-08-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-07-9

CMF C17 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-10-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-09-1

CMF C23 H26 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-26-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-25-1

CMF C19 H16 Cl2 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749


CRN 691405-27-3
CMF C25 H20 Cl2 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-45-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-44-4
CMF C21 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-48-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-47-7
CMF C27 H26 N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691405-64-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[2-methoxyphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-63-7
CMF C19 H18 N6 O

10/759,749




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-66-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-65-9

CMF C25 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749




RN 691405-82-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-81-9

CMF C18 H15 F N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-84-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-83-1

CMF C24 H19 F N6 O

10/759,749




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-00-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-99-9

CMF C14 H16 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-02-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749


CRN 691406-01-6
CMF C20 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691406-08-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691406-07-2
CMF C18 H16 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:107925 CAPLUS
 DN 140:303243
 TI Two-photon absorption properties of star-shaped compounds based on
 1,3,5-triazine and 1,3,5-trisubstituted benzene
 AU Zhou, Xin; Ren, Ai-Min; Feng, Ji-Kang; Liu, Xiao-Juan
 CS Institute of Theoretical Chemistry, State Key Laboratory of Theoretical
 and Computational Chemistry, Jilin University, Changchun, 130023, Peop.
 Rep. China
 SO THEOCHEM (2004), 668(2-3), 229-234
 CODEN: THEODJ; ISSN: 0166-1280
 PB Elsevier Science B.V.
 DT Journal
 LA English
 IT 676520-46-0
 RL: PRP (Properties)
 (two-photon absorption properties of star-shaped compds. based on
 1,3,5-triazine and 1,3,5-trisubstituted benzene)
 RN 676520-46-0 CAPLUS
 CN 2,4,6-Pyrimidinetriamine, N,N,N',N',N'',N''-hexa-2-pyridinyl- (9CI) (CA
 INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:356443 CAPLUS
 DN 138:368916
 TI Preparation of heteroarylamines as glycogen synthase kinase 3beta
 inhibitors
 IN Freyne, Eddy Jean Edgard; Buijnsters, Peter Jacobus Johannes Antonius;
 Willems, Marc; Embrechts, Werner Constant Johan; Love, Christopher John;
 Janssen, Paul Adriaan Jan; Lewi, Paulus Joannes; Heeres, Jan; De Jonge,
 Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Van
 Aken Koen, Jeanne Alfons; Diels, Gaston Stanislas Marcella
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2003037891 A1 20030508 WO 2002-EP12077 20021029
 WO 2003037891 C1 20030904
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2463822 AA 20030508 CA 2002-2463822 20021029
 EP 1448556 A1 20040825 EP 2002-790307 20021029
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002013792 A 20041207 BR 2002-13792 20021029
 CN 1582285 A 20050216 CN 2002-821900 20021029
 JP 2005507423 T2 20050317 JP 2003-540172 20021029
 US 2005004125 A1 20050106 US 2004-493452 20040423
 NO 2004001911 A 20040510 NO 2004-1911 20040510
 PRAI EP 2001-204196 A 20011101
 WO 2002-EP12077 W 20021029

OS MARPAT 138:368916


IT 521951-07-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylamine derivs. as glycogen synthase kinase 3 β (GSK3 β) inhibitors for preventing or treating GSK3 β -mediated diseases)

RN 521951-07-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-bromo-2-pyridinyl)-N4-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:300895 CAPLUS

DN 138:321288

TI Preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring for use as kinase inhibitors in the treatment of cancer

IN Nagarathnam, Dhanapalan; Wang, Chunguang; Chen, Yuanwei; Yi, Lin; Chen, Jianqing; Weber, Olaf; Boyer, Stephen; Clark, Roger B.; Phillips, Barton; Meahl, Jennifer; Ladouceur, Gaetan; Bi, Cheng; Burke, Michael J.; Cook, James; Verma, Sharad K.; Fan, Jianmei

PA Bayer Corporation, USA

SO PCT Int. Appl., 118 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030909	A1	20030417	WO 2002-US30616	20020925
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-324276P	P	20010925		
	US 2002-352509P	P	20020131		
OS	MARPAT 138:321288				
IT	511245-40-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)				
RN	511245-40-2	CAPLUS			
CN	2,4-Pyrimidinediamine, N,N'-di-3-isoquinoliny- (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1956:56933 CAPLUS

DN 50:56933

OREF 50:10729d-i,10730a-h

TI Quaternary salts from 2-chloro-5-nitropyrimidines. I. Preparation and some reactions

AU Spickett, R. G. W.; Timmis, G. M.

CS Roy. Cancer Hosp., London

SO Journal of the Chemical Society (1955) 4354-9

CODEN: JCSOA9; ISSN: 0368-1769

DT Journal

LA Unavailable


IT 733039-53-7, Pyrimidine, 4-amino-5-nitro-2-(2-pyridylamino)-
 857428-16-1, Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-pyridylamino)-
 5-nitro- 874494-56-1, Pyrimidine, 2,4-bis(6-methyl-2-

10/759,749

pyridylamino)-5-nitro-
(preparation of)

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857428-16-1 CAPLUS


CN Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874494-56-1 CAPLUS

CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1952:48660 CAPLUS

DN 46:48660

10/759,749

OREF 46:8121g-i,8122a-c

TI Quaternary salts from 2-chloro-5-nitropyrimidines, and their reactions

AU Spickett, R. G. W.; Timmis, G. M.

CS Roy. Cancer Hosp., London

SO Chemistry & Industry (London, United Kingdom) (1951) 937-9

CODEN: CHINAG; ISSN: 0009-3068


DT Journal

LA Unavailable

IT 859208-12-1, Pyrimidine, 4-anilino-5-nitro-2-(2-pyridylamino)-
874494-56-1, Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro-
(preparation of)

RN 859208-12-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874494-56-1 CAPLUS

CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1948:32077 CAPLUS

DN 42:32077

OREF 42:6830e-i,6831a

TI Synthetic antimalarials. XXVI. Pyridyl- and pyrimidylaminopyrimidines

AU Curd, F. H. S.; Graham, W.; Rose, F. L.

CS Imp. Chem. Industries Ltd., Blackley, UK

SO Journal of the Chemical Society (1948) 594-7

CODEN: JCSOA9; ISSN: 0368-1769


DT Journal

LA Unavailable

IT 856851-88-2, Pyrimidine, 4-(2-diethylaminoethylamino)-6-methyl-2-(2-pyridylamino)-, dihydrochloride 856855-34-0, Pyrimidine, 4-methyl-6-p-nitroanilino-2-(2-pyridylamino)-, dihydrochloride 856976-15-3, Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride


10/759,749

(preparation of)
RN 856851-88-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 856855-34-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 856976-15-3 CAPLUS
CN Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride (5CI) (CA INDEX NAME)



● 2 HCl

10/759,749

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

53.11

220.26

STN INTERNATIONAL LOGOFF AT 13:44:25 ON 14 JUL 2006